Company Name, Ticker, Suppliers, else..

Astrazeneca Plc (NASDAQ: AZN)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Astrazeneca Plc Growth Comparisons

Select each growth Category to receive further Information

Select the Comparisons :

Growth Rates ▼

Select the Ratio:

None▼

Growth Rates ▼

None▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AZN Revenue Growth Rate Comparisons	Company	Industry	Sector	S&P 500
Y / Y Revenue Growth (Q4 MRQ)	8.63 %	11.97 %	3.9 %	5.68 %
Q / Q Revenue Growth (Q4 MRQ)	-	3.64 %	2.5 %	2.63 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM)	9.23 %	40.43 %	22.92 %	%
Sequential Revenue Growth (for 12 months ending Q4 TTM)	-	36.47 %	18.35 %	1.74 %
Revenue 5 Year Average Growth	17.15 %	14.14 %	10.99 %	7.73 %

AZN's Growth Comparisons in IV. Quarter 2025

Astrazeneca Plc's 8.63% year on year Revenue increase in the fourth quarter 2025 to 58.74 billions, marks slow-down from Astrazeneca Plc's growth trends, and competes unfavorably to the 11.97% rise in the Major Pharmaceutical Preparations industry, but beating the 3.9% growth in the Healthcare sector. Observing the fourth quarter sales growth, both Major Pharmaceutical Preparations industry and Astrazeneca Plc outperformed 5.68% overall market increase.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by 17.15% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 7.73%.

AZN Growth Rates by Company's Segments

Segment Name	Y / Y	Sequential
US	-	-
Emerging Markets	-	-
Europe	-	-
Rest of World	-	-
Total Oncology	-	-
Total Oncology US	-	-
Total Oncology Emerging Markets	-	-
Total Oncology Europe	-	-
Total Oncology Rest of World	-	-
Tagrisso	-	-
Tagrisso US	-	-
Tagrisso Emerging Markets	-	-
Tagrisso Europe	-	-
Tagrisso Rest of World	-	-
Imfinzi	-	-
Imfinzi US	-	-
Imfinzi Emerging Markets	-	-
Imfinzi Europe	-	-
Imfinzi Rest of World	-	-
Calquence	-	-
Calquence US	-	-
Calquence Emerging Markets	-	-
Calquence Europe	-	-
Calquence Rest of World	-	-
Lynparza	-	-
Lynparza US	-	-
Lynparza Emerging Markets	-	-
Lynparza Europe	-	-
Lynparza Rest of World	-	-
Enhertu	-	-
Enhertu Emerging Markets	-	-
Enhertu Europe	-	-
Enhertu Rest of World	-	-
Zoladex	-	-
Zoladex US	-	-
Zoladex Emerging Markets	-	-
Zoladex Europe	-	-
Zoladex Rest of World	-	-
Truqap	-	-
Truqap US	-	-
Truqap Emerging Markets	-	-
Truqap Europe	-	-
Truqap Rest of World	-	-
Imjudo	-	-
Imjudo US	-	-
Imjudo Emerging Markets	-	-
Imjudo Europe	-	-
Imjudo Rest of World	-	-
Datroway	-	-
Datroway Emerging Markets	-	-
Oncology Others	-	-
Oncology Others US	-	-
Oncology Others Emerging Markets	-	-
Oncology Others Europe	-	-
Oncology Others Rest of World	-	-
CVRM	-	-
CVRM US	-	-
CVRM Emerging Markets	-	-
CVRM Europe	-	-
CVRM Rest of World	-	-
Farxiga	-	-
Farxiga US	-	-
Farxiga Emerging Markets	-	-
Farxiga Europe	-	-
Farxiga Rest of World	-	-
Crestor	-	-
Crestor US	-	-
Crestor Emerging Markets	-	-
Crestor Europe	-	-
Crestor Rest of World	-	-
Brilinta	-	-
Brilinta US	-	-
Brilinta Emerging Markets	-	-
Brilinta Europe	-	-
Brilinta Rest of World	-	-
Lokelma	-	-
Lokelma US	-	-
Lokelma Emerging Markets	-	-
Lokelma Europe	-	-
Lokelma Rest of World	-	-
Seloken	-	-
Seloken Emerging Markets	-	-
Seloken Europe	-	-
Seloken Rest of World	-	-
Roxadustat	-	-
Roxadustat Emerging Markets	-	-
Wainua	-	-
Wainua US	-	-
Wainua Emerging Markets	-	-
Wainua Europe	-	-
CVRM Others	-	-
CVRM Others US	-	-
CVRM Others Emerging Markets	-	-
CVRM Others Europe	-	-
CVRM Others Rest of World	-	-
Total Respiratory Immunology	-	-
Total Respiratory Immunology US	-	-
Total Respiratory Immunology Emerging Markets	-	-
Total Respiratory Immunology Europe	-	-
Total Respiratory Immunology Rest of World	-	-
Symbicort	-	-
Symbicort US	-	-
Symbicort Emerging Markets	-	-
Symbicort Europe	-	-
Symbicort Rest of World	-	-
Fasenra	-	-
Fasenra US	-	-
Fasenra Emerging Markets	-	-
Fasenra Europe	-	-
Fasenra Rest of World	-	-
Breztri	-	-
Breztri US	-	-
Breztri Emerging Markets	-	-
Breztri Europe	-	-
Breztri Rest of World	-	-
Tezspire	-	-
Tezspire Emerging Markets	-	-
Tezspire Europe	-	-
Tezspire Rest of World	-	-
Saphnelo	-	-
Saphnelo US	-	-
Saphnelo Emerging Markets	-	-
Saphnelo Europe	-	-
Saphnelo Rest of World	-	-
Pulmicort	-	-
Pulmicort US	-	-
Pulmicort Emerging Markets	-	-
Pulmicort Europe	-	-
Pulmicort Rest of World	-	-
Airsupra	-	-
Airsupra US	-	-
Airsupra Emerging Markets	-	-
Respiratory and immunology Others	-	-
Respiratory and immunology Others US	-	-
Respiratory and immunology Others Emerging Markets	-	-
Respiratory and immunology Others Europe	-	-
Respiratory and immunology Others Rest of World	-	-
Vaccines Immune Therapies	-	-
Vaccines Immune Therapies US	-	-
Vaccines Immune Therapies Emerging Markets	-	-
Vaccines Immune Therapies Europe	-	-
Vaccines Immune Therapies Rest of World	-	-
Beyfortus	-	-
Beyfortus US	-	-
Beyfortus Europe	-	-
Beyfortus Rest of World	-	-
Synagis	-	-
Synagis US	-	-
Synagis Emerging Markets	-	-
Synagis Europe	-	-
Synagis Rest of World	-	-
FluMist	-	-
FluMist US	-	-
FluMist Emerging Markets	-	-
FluMist Europe	-	-
FluMist Rest of World	-	-
Vaccines Immune Therapies Others	-	-
Vaccines Immune Therapies Others Emerging Markets	-	-
Total Rare Disease	-	-
Total Rare Disease US	-	-
Total Rare Disease Emerging Markets	-	-
Total Rare Disease Europe	-	-
Total Rare Disease Rest of World	-	-
Ultomiris	-	-
Ultomiris US	-	-
Ultomiris Emerging Markets	-	-
Ultomiris Europe	-	-
Ultomiris Rest of World	-	-
Soliris	-	-
Soliris US	-	-
Soliris Emerging Markets	-	-
Soliris Europe	-	-
Soliris Rest of World	-	-
Strensiq	-	-
Strensiq US	-	-
Strensiq Emerging Markets	-	-
Strensiq Europe	-	-
Strensiq Rest of World	-	-
Koselugo	-	-
Koselugo US	-	-
Koselugo Emerging Markets	-	-
Koselugo Europe	-	-
Koselugo Rest of World	-	-
Rare Disease Others	-	-
Rare Disease Others US	-	-
Rare Disease Others Emerging Markets	-	-
Rare Disease Others Europe	-	-
Rare Disease Others Rest of World	-	-
Total Other medicines	-	-
Total Other medicines US	-	-
Total Other medicines Emerging Markets	-	-
Total Other medicines Europe	-	-
Total Other medicines Rest of World	-	-
Nexium	-	-
Nexium US	-	-
Nexium Emerging Markets	-	-
Nexium Europe	-	-
Nexium Rest of World	-	-
Other Others	-	-
Other Others US	-	-
Other Others Emerging Markets	-	-
Other Others Europe	-	-
Other Others Rest of World	-	-
Other royalty income	-	-
Other Alliance Revenue	-	-
Farxiga sales milestones	-	-
Other Collaboration Revenue	-	-
UNITED KINGDOM	-	-
Outside the UK	-	-
Rest of Europe	-	-
FRANCE	-	-
GERMANY	-	-
ITALY	-	-
SPAIN	-	-
SWEDEN	-	-
Others Europe	-	-
The Americas	-	-
CANADA	-	-
Other Americas excluding US and Canada	-	-
Asia Africa And Australasia	-	-
AUSTRALIA	-	-
CHINA	-	-
JAPAN	-	-
Other Asia Africa and Australasia excluding Australia China and Japan	-	-
Customer one	-	-
Customer two	-	-
Total	-	-

Growth Rates of AZN's Income in the fourth quarter 2025

AZN Operating Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Operating Income Change (Q4 MRQ)	37.39 %	163.92 %	43.13 %	-0.27 %
Sequential Operating Income Change (Q4 MRQ)	-	-36.21 %	-18.21 %	-8.98 %
Y / Y Operating Income Growth (Q4 TTM)	35.31 %	19.47 %	20.16 %	9.24 %
Sequential Operating Income Growth (Q4 TTM)	27.68 %	15.85 %	8.88 %	-0.22 %
Operating Income 5 Year Avg. Change	21.63 %	0.11 %	-0.96 %	9 %

Income from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ)	45.33 %	-	-92.49 %	22.99 %
Sequential Income from Cont. Ops. Change (Q4 MRQ)	-	-	-92.34 %	8.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM)	45.33 %	19.86 %	64.46 %	11.58 %
Sequential Income from Cont. Ops. Change (Q4 TTM)	45.33 %	10.92 %	43.11 %	4.61 %
Income from Cont. Ops. 5 Year Avg. Change	26.62 %	-18.69 %	-17.93 %	8.34 %

AZN Net Income Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y Net Income Growth (Q4 MRQ)	45.33 %	124.96 %	34.43 %	25.85 %
Q / Q Net Income Growth (Q4 MRQ)	-	18.2 %	-22.85 %	7.59 %
Y / Y Net Income Change (Q4 TTM)	41.39 %	79.49 %	65.39 %	9.66 %
Sequential Net Income Change (Q4 TTM)	33.64 %	111.37 %	70.85 %	5.18 %
Net Income 5 Year Avg. Growth	26.62 %	14.51 %	6.2 %	9.47 %

AZN's EPS Growth Rates

EPS from Cont. Ops. Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ)	-	-	-92.49 %	22.99 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ)	-	-	-92.34 %	8.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM)	27.14 %	-	-	-
Sequential EPS from Cont. Ops. Change (Q4 TTM)	0 %	-	-	33 %
EPS from Cont. Ops. 5 Year Avg. Growth	6.25 %	-29.47 %	-17.93 %	8.34 %

AZN EPS Net Growth Rates Comparisons	Company	Industry	Sector	S&P 500
Y / Y EPS Net Growth (Q4 MRQ)	-	113.67 %	34.43 %	8.34 %
Q / Q EPS Net Growth (Q4 MRQ)	-	20.77 %	-22.85 %	7.59 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM)	-	-	-	92.65 %
Sequential EPS Net Change (for 12 months ending Q4 TTM)	0 %	-	-	33 %
EPS Net 5 Year Avg. Change	6.1 %	14.51 %	6.2 %	9.47 %

Astrazeneca Plc reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 113.67%, while Healthcare sector increased by 34.43%, and overall market improved by 25.85%.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by 6.1% on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 9.47%.

AZN Cash Flow Growth Rates

Free Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ)	18.4 %	56.01 %	46.59 %	32.85 %
Sequential Free Cash Flow Change (Q4 MRQ)	-	-26.02 %	-0.82 %	113.08 %
Y / Y Free Cash Flow Change (Q4 TTM)	18.4 %	13.97 %	16.86 %	10.44 %
Sequential Free Cash Flow Change (Q4 TTM)	18.4 %	8.12 %	8.13 %	9.43 %
Free Cash Flow 5 Year Avg. Change	24.29 %	9.45 %	6.34 %	10.76 %

Net Cash Flow Growth Rates	Company	Industry	Sector	S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ)	-	-83.27 %	-	-81.15 %
Sequential Net Cash Flow Change (Q4 MRQ)	-	-	-	-
Y / Y Net Cash Flow Change (Q4 TTM)	-	-1 %	0.04 %	-
Sequential Net Cash Flow Change (Q4 TTM)	-	25.87 %	111.57 %	-
Net Cash Flow 5 Year Avg. Change	-	-8.21 %	-1.7 %	-32.35 %

Capital Expenditures	Company	Industry	Sector	S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ)	46.05 %	2.15 %	7.41 %	22.34 %
Sequential Capital Expenditures Change (Q4 MRQ)	-	25.33 %	22.68 %	17.09 %
Y / Y Capital Expenditures Change (Q4 TTM)	46.05 %	13.78 %	7.84 %	41.57 %
Sequential Capital Expenditures Change (Q4 TTM)	46.05 %	12.29 %	6.37 %	6.83 %
Capital Expenditures 5 Year Avg. Change	23.94 %	10.12 %	8.7 %	10.66 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Valuation Comparisons

Management Effectiveness

Financial Strength

Efficiency

Dividend Comparisons

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.